Innovation management in healthcare: Where are we going?

Call for papers for: European Journal of Innovation Management

Guest Editors
Francesco Schiavone, University of Naples Parthenope, Department of Management and Quantitative Studies, Italy, [email protected]
David W. Versailles, Paris School of Business, newPIC Chair, France, [email protected] 
Valerie Merindol, Paris School of Business, newPIC Chair, France, [email protected] 
Uta Wilkens, Ruhr-Universität Bochum (RUB) – Institute of Work Science (IAW) – Chair for Work, Human Resources and Leadership, [email protected] 

Statement of aims
Healthcare was a domain at ease with the cascade or techno-push model of innovation, with a special attention on experimentation structured by legal test protocols. The management of innovation in healthcare has attracted renewed attention with the reference to AI, “big data”, biotechs, medtechs and with the reference to user-centric innovation (as most often illustrated with medtechs and biotechs). Research in healthcare is as complex and risky as ever, but time frames for the development of innovation have adapted to the new realities of AI and biotechs, and the scope of experimentation to new stakeholders. Disruptive innovation in healthcare is a crucial driver for the evolution for this industry over the last years. 
Top-down and user-centric innovation management are not in opposition; they complement each other in different areas of healthcare research, and at different stages of innovation processes. Both processes co-exist for the management of innovation today and have to invent how to complement each other. The twin reference to deeptechs and to digitalization has also reshaped how to process research and generate innovation in healthcare: new stakeholders now jump into the domain without prior vicinity with the its specificities as regards safety, legal issues or mandatory experimentation and validation protocols (as illustrated in medtechs, where lots of innovators directly come from computer sciences and other domains in physics).However, the stakeholders contributing to these processes do not follow the same rationales, and do not always understand each other. These aspects now require new and adapted practices in the management of innovation. This evolution develops also in an external environment framed by the rapid aging of world population, the difficult access to medical care for some social groups due to increasing budget constraints by national Governments, and the urgency incurred by specific diseases (e.g. the COVID pandemic). 

This special issue focuses on new practices for the management of innovation in all subareas of healthcare. The special issues covers the development of user-centric innovation and of experimentation to healthcare, with a special focus on its complementarities with traditional cascade top-down (techno-push) innovation. User-centric innovation in healthcare makes it also possible to test new business models with the appropriate stakeholders. The healthcare domain is original because it provides field research to analyze the dynamics in the Triple or Quadruple Helix (State, research, industry, actual people) and the interactions between them in local ecosystems. It provides also a relevant domain to question the status of "user" in user-centric innovation.
The aim of this special issue is to collect high-quality papers addressing and contributing to the debate about the main criticalities of the innovation management in healthcare systems and organizations. 
Drawing from the research directions presented earlier in this section, this call for papers seeks empirical and conceptual contributions that critically analyse the current state of top-down and user-centric innovation management in the healthcare sector. We welcome contributions about the articulation between these two approaches, and about the renewal of innovation management practices incurred by current technological disruptions, by the presence of more diverse stakeholders, and by the arrival of new innovation actors without any prior vicinity with healthcare (as medtechs most often illustrate it). 
Other topics may cover the main macro-, meso-, and micro-level conditions (e.g., institutions and regulations, and pricing and reimbursement, adaptation of existing business models, introduction of innovative business models, supply-chain management) of innovation management in healthcare.  

We also welcome papers exploring new methods to conduct research and analyse data in light of new innovations and technological disruption in the healthcare industry.

Authors are invited to submit theoretical and empirical papers that would contribute to fulfilling the aims of the special issue.

Topics of interest include but are not limited to:

  • Current practices for top-down (techno-push) innovation management in healthcare
  • Current practices for user-centric innovation in healthcare
  • Complementarities between techno-push and user-centric innovation in healthcare
  • Management of technological disruptions in healthcare systems (AI, "big data")
  • Management of biotech-related disruptions in healthcare systems
  • New theoretical models and practice-based methods for innovation management in healthcare
  • New product and service development in health ecosystems
  • Adoption and diffusion of digital innovation in healthcare markets and ecosystems
  • Adoption and diffusion of user-centric innovation
  • Mixing disruptive innovation and radical innovation in health
  • Lead users and bottom-up innovation in health sectors
  • Managing (and profiting from) health innovation
  • Gender impact of innovation management in health services
  • Managing innovation-driven health service ecosystems
  • New roles for innovation intermediaries in healthcare services
  • Dynamics and specificities of Triple/ Quadruple Helix models in healthcare (medtechs, biotechs, e-healthcare)
  • Role and influence of regulation for the management of innovation in healthcare
  • Improved theoretical models for the management of user centric innovation
  • New business model and business model innovation in regulated environments
  • Managing process innovation in healthcare systems
  • ICT, social media and innovation management of healthcare.

References
AGOGUÉ, M., BERTHET, E., FREDBERG, T., LE MASSON, P., SEGRESTIN, B., STOETZEL, M., YSTRÖM, A. (2017), Explicating the role of innovation intermediaries in the “unknown”: a contingency approach, Journal of Strategy and Management, 10(1), 19-39.
BULLINGER, A.C., RASS, M., ADAMCZYK, S., MOESLEIN, K.M., SOHN, S., (2012), Open Innovation in Health Care: Analysis of an Open Health Platform. Health Policy 105 (2), 165-175.
Carayannis, E. G., & Campbell, D. F. J. (2009). “Mode 3 and Quadruple Helix: toward a 21st century fractal innovation ecosystem.” International Journal of Technology Management, 46(3/4), 201–234.
Chesbrough, H., Vanhaverbeke, W., & West, J. (Eds.). (2006). Open innovation: Researching a new paradigm. Oxford University Press on Demand.
Cohendet, P. Grandadam D., Simon L. and Capdevila I. (2014). “Epistemic communities, localization and the dynamics of knowledge creation”. Journal of economic geography 14(5), 929-954. 
Dougherty, D. and D. D. Dunne (2011). “Organizing ecologies of complex innovation.” Organization Science, 22(5), 1121-1367. 
Dougherty, D. and T. Heller (1994). “The illegitimacy of successful product innovation in established firms”. Organization Science, 5(2), 121-287. 
GITTELMAN, M. (2016), The Revolution Re-visited: Clinical and Genetics Research Paradigms and the Productivity Paradox in Drug Discover, Research Policy, 45, 1570-1585 
Haas, P. M. (1989). “Do Regimes Matter? Epistemic Communities and Mediterranean Pollution”, International Organization, 43/3, 377-403.
Haas, P. M.(1992). “Epistemic Communities and International Policy Coordination”, International Organization, 46/1, 1-35.
HYYSALO, S. et HAKKARAINEN L. (2014), What difference does a living lab make? Comparing two health technology innovation projects, CoDesign: International Journal of CoCreation in Design and the Arts, 10:3-4, 191-208
KERA, D. (2013), Innovation Regimes Based on Collaborative and Global Tinkering: Syntetic Biology and Nanotechnology in the Hakerspaces, Technology in society, 37, 28-37. 
KIMBLE, C., GRENIER, C., GOGLIO-PRIMARD, K., (2010), Innovation and Knowledge Sharing Across Professional Boundaries: Political Interplay Between Boundary Objects and Brokers, International Journal of Information Management, 30(5), 437-444.
KODOMA, M. (2015), Collaborative Innovation: Developing Health Support Ecosystems, Routledge, New York. 
Leydesdorff, L. and H. Etkowitz (1996). “Emergence of a Triple Helix of university, industry, government relations.” Science and Public Policy, 23(5), Oct., 279-286. 
MCCOLL-KENNEDY, J.R., VARGO, S.L., TRACEY, S., DAGGER, J.C., SWEENEY, J.C., VAN KASTEREN, Y. (2012), Health Care Customer Value Cocreation Practices Styles, Journal of Service Research, 15(4), 370-389. 
MILAN, S., FAYOLLE, A., LAMINE, W. (2005), Building Sustainable Regional Platforms for Incubating Science and Technology Business: Evidence from US and French Science and Technology parks, Entrepreneurship and Innovation, 13(4), 235-247 
SAIDI, T., DE VILLIERS, K., DOUGLAS, T.S. (2017), The Sociology of Space as a Catalyst for Innovation in the Health Sector, Social Science & Medicine, 180, 36-44
THUNE, T., MINA, A. (2016), Hospitals as Innovators in the Healthcare System: a Literature Review and Research Agenda, Research Policy, 45, 1545-1557. 
Urban, G. L. and Von Hippel, E. (1988). Lead User analyses for the development of new industrial products. Management Science, 34(5), p.569-582.

Publication Schedule

  • Manuscript submission: 31 December 2020
  • Reviewer reports: 30 March 2021
  • Final paper submission: 30 July 2021
  • Anticipated publication date of the special issue electronic from October 2021
  • Anticipated publication date of the special issue print March 2022

All submissions must be done through ScholarOne

Guest editors’ Bios
Francesco Schiavone, Ph.D., is associate professor in Management at University of Naples Parthenope (Italy). He has been working in the field of healthcare innovation and management for many years. He published various articles about digital transformation and adoption of information systems in healthcare organizations, market access and value co-creation, and patient management via artificial intelligence. He is currently the scientific director of a research project about the evaluation of performance of the Campania Cancer Network (Italy). His latest book is about user innovation by patients and caregivers (to be published by Springer in 2020).

David W. Versailles is Full Professor of strategic management and innovation studies at Paris School of Business where he jointly heads the newPIC chair with Valerie Merindol since 2014. The newPIC chair specializes in the management of innovation and creativity. Recent projects relate to the management of open innovation laboratories and of innovation platforms, with field research in AI, data science, biotechs, and healthcare. David W. Versailles is principal investigators and research program director with Valerie Merindol for projects commissioned by different French institutions, most notably the French Ministry of Defense, the French governmental office BPIFRANCE, and the biocluster Genopole. Prof. Versailles is also Invited Full Prof of strategic management at Luxembourg School of Business.

Valerie Merindol is Full Professor of Innovation at Paris School of Business where she jointly heads the newPIC chair with David W. Versailles since 2014. The newPIC chair specializes in the management of innovation and creativity. Recent projects relate to the management of open innovation laboratories and of innovation platforms, with field research in AI, data science, biotechs, and healthcare. Valerie Merindol is principal investigators and research program director with David W. Versailles for projects commissioned by different French institutions, most notably the French Ministry of Defense, the French governmental office BPIFRANCE, and the biocluster Genopole. 

Uta Wilkens is Full Professor in Work, Human Resources and Leadership (since 2005) and since 2018 Director of the Institute of Work Science at RUB. Recent research builds on the human-centricity of artificial intelligence (AI) in the workplace and the social acceptance of AI as a prerequisite for exploiting the innovation potential in terms of better life and high quality work standards. Her expertise includes different branches coping with digital services and smart solutions: manufacturing industries, hospitals and agriculture. During the last ten years she acquired more than 3 Mio. Euro third-party funds (DFG, BMBF, EU) and was member of the SFB TR29 “Engineering hybrider Leistungsbündel” (Engineering Industrial Product-Service-Systems). Prof. Wilkens is member of certain scientific advisory boards for public and private institutions.